Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Clinical Trials
ALISCA™-Breast1 Active Sites - Europe
Puma anticipates opening the ALISCA™-Breast1 trial at approximately 50 study sites within the United States and Europe. Below is a list of sites currently open to enrollment as of 18JUN2025. Please note study site availability for enrollment is subject to change without notice. Please contact Puma at clinicaltrials@pumabiotechnology.com should you have any questions regarding open sites.